Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Trilaciclib is a highly potent, selective, and reversible CDK4/6 inhibitor that protects bone marrow by protecting hematopoietic stem cells and progenitor cells (HSPCs) during systemic chemotherapy. The proliferation and differentiation of HSPCs are highly dependent on the CDK4/6 signaling pathway, and when exposed to the appropriate dose of treacilil, they will be blocked in the G1 phase of the cell cycle, thus avoiding the killing of cell cycle-specific chemotherapy drugs. This is an open, single-arm, multicenter Phase II clinical study. Newly diagnosed TNBC patients with T1c N1-2 or T2-4 N0

Trial Details

NCT ID

NCT06955156

Phase

PHASE2

Sponsor

QIAO LI

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• Trilaciclib

Locations (sample)

• Beijing, China|39.9075,116.39723

Key Eligibility Criteria

• Patients fully understand and voluntarily participate in this study and sign the informed consent form.
• Age ≥18 and ≤75 years.
• Newly diagnosed TNBC with stage T1c N1-3 or stage T2-4 N0-3.
• Patients scheduled to receive neoadjuvant therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →